Medically reviewed by Jessica Swirble, PharmDLast updated on March 26, 2025
Drug Information| | |
Uses
The goal of this research is to understand how Baclofen works in the brain. Baclofen is a drug that belongs to a group of drugs called GABA agonists. Baclofen works by increasing the levels of neurotransmitters, which are chemicals in the brain. These chemicals send nerve cells to stimulate their activity. Baclofen is approved for the treatment of conditions such as multiple sclerosis, spinal cord injuries, and other neurological conditions.
is the brand name for a medication that belongs to a group of drugs called baclofen. This class of drugs treats conditions such as multiple sclerosis, spinal cord injuries, and other neurological conditions. Baclofen Intrathecal is FDA-approved to treat:
is also the brand name for a medication that belongs to a group of drugs called baclofen. This group of drugs treats conditions such as multiple sclerosis, spinal cord injuries, and other neurological conditions.
Baclofen Tabletsare the brand name for a medication that is injected at least 12 hours before the injection or for 4 to 6 weeks. This is done to reduce the risk of side effects. Baclofen Subcutaneous Solution (BBS) is a low-cost form of baclofen. It is available as an injection for patients who cannot afford to pay for a baclofen tablet.
Baclofen Subcutaneous Solutionis a injectable form of baclofen. It is an oral solution that is taken by mouth.
Intrathecal Baclofenis the generic name for a medication that is injected by a healthcare provider. Baclofen Intrathecal is also the brand name for a medication that is given by a healthcare provider. Baclofen Intrathecal is approved to treat:
Preparation and UsageBaclofen Intrathecal is typically injected into the spinal cord of a patient.The most common initial dose of baclofen is 10 mg/kg once daily, which is then titrated to a total of 20 mg/kg once daily. After this dose, the patient may be titrated to 10 mg/kg every other day, depending on the patient’s response and tolerability.
The most common initial dose of baclofen is 20 mg/kg once daily, which is then titrated to a total of 30 mg/kg once daily. The patient may be titrated to 30 mg/kg every other day, depending on their response and tolerability. The dose may be increased to 40 mg/kg, or the dose may be titrated to a total of 60 mg/kg once daily.
Before you take a dose of baclofen, read the manufacturer's information leaflet.
What is this medicine?
BACLOFEN contains an active ingredient called Lioresal. It belongs to a group of medicines known asmuscle relaxants.They work bystimulating nerve impulses,relaxing the musclesandrelaxing blood vessels.Baclofen relaxes the muscles and dilates the blood vessels. This action helps toincrease oxygenation of blood vesselsrelax the heart muscle. It alsotreats arrhythmias, muscle spasmstinnitus (feeling of heat).
This medicine should be used only when required.
This medicine is not recommended for use in children under 14 years of age.
Do not take baclofenwithanymedication for erectile dysfunction.
Do not give to children under 14 years.
The information provided here is general information about baclofen.Copyright © 2005. Physicians information.
Read and follow each medication's manufacturer's information leaflet provided with each prescription.Baclofen contains an active ingredient called Lioresal.stabilizing the musclesand the heart muscle.tinnitus (feeling of heat)
Baclofen is available in the following strengths:10mg, 20mg, 40mg and 80mg.
Your doctor will prescribe the lowest effective dose for you based on your medical condition and the severity of your symptoms. Do not give to children under 14 years of age unless your doctor tells you to.
Baclofen is not recommended for use in pregnant women unless necessary.
20mg, 40mg and 80mg.
Baclofen, a medication primarily used to treat muscle spasms caused by neurological conditions such as multiple sclerosis, spinal cord injuries, and other neurological disorders, is experiencing significant growth in the global pharmaceutical market. Here’s a comprehensive analysis of the baclofen market, including its current state, future projections, and key drivers.
As of 2024, the global baclofen market was valued at approximately USD 16,524.27 million. It is projected to grow at a compound annual growth rate (CAGR) of 11.4% from 2024 to 2034, reaching a market size of USD 30,976.43 million by 2034[1].
North America dominates the global baclofen market, accounting for around 38% of the market share in 2023. This dominance is attributed to the high prevalence of neurological conditions such as multiple sclerosis and spinal cord injuries in the region, particularly in the United States. The well-developed healthcare infrastructure, high healthcare spending, and widespread awareness of treatment options also contribute to this market leadership[1].
The Asia-Pacific region is also the major market player, with countries like Russia, India, and China bearing the brunt of significant growth driven by rising medical expenditure. The region’s high incidence of stroke, high cardiovascular economy, and rising incidence of infections such as infections of the central nervous system, obesity, and diabetes are also impacting the market[1].
The average baclofen usage in the U. was$ the most important factor for the market, with a cost-of-illness jab of $32.09 million and cost-of-sixth to bebid ratio of product equivalent of$26.4of cost-sharing. This is around 6.2% more than the average jab, with products like Baclofen for treatment of multiple sclerosis valued at1.2- 1.4% more. As of 2034, there have been multiple multiple sclerosis (MSE) treatments available, such as Lupin, Actonel, and Lyrica, with the cost-sharing of all products appreciated at prices around3.7- 3.8% more[2].
The baclofen market is analyzed in terms of price variation and multiple sclerosis treatment options. Countries with varying healthcare costs and differences in treatment approaches are factors driving the market growth. Countries with consistent healthcare expenditure and differences in treatment approaches are also factors contributing to market growth[1].
The future outlook for the baclofen market is positive, with some studies indicating a positive outlook for the future. Around 11% points points towards further development of the market, with significant demand in certain regions driving the market increasing in demand.
A group of researchers has recently published a paper highlighting the potential for the drug to treat alcohol addiction. The paper shows that the drug has been shown to cause a number of adverse reactions, including:
The researchers believe this finding is a significant contribution to the broader understanding of the mechanism of alcohol addiction.
“The use of this medication may have a direct effect on the body’s alcohol metabolism, which can be harmful to patients and can lead to excessive drinking.”
“The drug has also been shown to reduce the effects of alcohol in a small number of patients,” said in part by highlighting the use of baclofen to treat alcohol use disorder. “This study highlights the potential for this medication to be a valuable tool in the treatment of alcohol addiction.”
The authors said the study supports the need for further research to determine the effects of baclofen on alcohol use disorder.
“This study demonstrates that baclofen is a promising treatment option for alcohol addiction,” said, a psychologist at the University of Oxford.
The team also highlighted how baclofen can have a potentially life-saving impact on the body. “Although we have not yet found a drug with this potential,” said the lead researcher,.
“This study provides a new avenue for the development of effective treatments for alcohol addiction,” said.
The study was published in the journalThe Journal of the American Medical Association, which is an online publication of the Society for Addiction and Mental Health in the United States.
The study is published online in the journalJAMA Internal Medicine.
Researchers from the University of Oxford and the Oxford-based, a UK-based university, conducted an extensive, randomized, controlled study of the drug to investigate the potential for baclofen to cause adverse reactions in alcohol use disorder patients. The study was funded by the National Institute for Drug Abuse (NIDA) and the National Institute for Health and Clinical Excellence (NICE).
The researchers recruited 9,000 patients with alcohol use disorder who were being treated with baclofen in the United States from 1998 to 2000.
In total, 7,734 patients were recruited.
The study participants were randomly assigned to receive baclofen (n=7,34) or placebo (n=4,38). The study participants were followed up on the same day for the entire first week. The patients were given a treatment protocol of standard treatment, and then were evaluated at the end of the second week.
The study participants received a treatment protocol of standard treatment, and then were evaluated at the end of the second week. The participants also received a treatment protocol of baclofen (n=4,38) or placebo (n=7,34).
The researchers found that baclofen was the most effective in treating alcohol use disorder. However, this effect was not seen in the placebo group.
The researchers found no significant differences in the rates of adverse reactions between the groups. However, baclofen was associated with fewer deaths in patients taking the drug.
In a separate study, the researchers reported that baclofen caused fewer deaths in patients taking the drug than placebo.
“Although we have not yet found a drug with this potential, baclofen has been shown to have a positive effect on alcohol addiction,” said the lead author,. “This study supports the need for further research to determine the effects of baclofen on alcohol addiction.”
The researchers believe that this study highlights the potential for baclofen to be a valuable tool in the treatment of alcohol addiction. The paper is published in the journal
The researchers also highlighted how baclofen may be used to treat patients with alcohol dependence.
“The use of baclofen has been shown to reduce the severity of alcohol dependence and enhance the therapeutic effect of the drug,” said.
The study was published inIt was a collaboration between the Oxford University and Oxford-based, the UK-based university. The research was funded by the National Institute for Drug Abuse.
The authors of the study included, the British Columbia Mental Health Alliance and the National Institute for Drug Abuse.
The combination of Baclofen and Spironolactone is effective in treating moderate to severe spinal spasticity, muscle spasms, and other spinal cord disorders. The combination may also be effective in managing other conditions related to low blood pressure.
Baclofen works by blocking the action of certain enzymes in the body. These enzymes play a role in regulating blood pressure and muscle contraction. Baclofen binds to these enzymes, preventing them from binding to target proteins. This interaction leads to a decrease in blood pressure and the release of certain chemicals into the spinal fluid.
The combination of Baclofen and Spironolactone has been shown to be effective in reducing spasticity, muscle spasms, and other spinal cord disorders. The combination is also being studied for other conditions that include multiple sclerosis, spinal cord injuries, cerebral palsy, and other neurological disorders.
Side effects associated with Baclofen include gastrointestinal disturbances, headache, diarrhea, dyspepsia, nausea, and nervousness. It is important to discuss any potential adverse effects with your doctor before starting this treatment.
Stade de France Pharmacy